The paper presents an overview of atrophic rhinitis, a common and widely spread infectious disease caused by Bordetella bronchiseptica. The main virulence factors of the pathogen are cell wall lipopolysaccharides, fimbriae, toxins, microcapsules, pertactin - like proteins. B. Bronchiseptica also produces tracheal cytotoxin, dermonecrotic toxin, adenylate cyclase-hemolysin, endotoxin. Clinically, the disease is manifested by progressive atrophy of the nasal bones, bronchopneumonia and / or sepsis, especially when associated with P. multocida, H. parasuis and S. suis or other bacterial and viral pathogens. The clinical manifestations of the disease include progressive atrophy of the nasal turbinate bones, bronchopneumonia and / or sepsis, especially when associated with P. multocida, H. parasuis and S. suis or other bacterial and viral pathogens. The diagnosis is established on the basis of clinical and epizootological data, the results of pathological, bacteriological and serological studies. For the treatment of the disease, antitussive antibiotic, antitussive, bronchodilators and anti-inflammatory drugs are prescribed. No domestic vaccines against atrophic rhinitis have been developed, which is why the work on the creation of new and improvement of existing means against atrophic rhinitis continues, including on the basis of Federal State Budget Scientific Institution «Federal Scientific Center VIEW» (FSC VIEV).